Page 222 - Mercy MOR All Regions_FinalwVideo

Key Performance Indicators Metric St. Elizabeth Youngstown Hospital % Variance -2.0% $29,056,687
Prior
Budget
Variance
Actual
($418)
0.0%
$7,443,118
$7,621,376
$7,443,536
Supply Expense
Net Patient Revenue
($595,380)
$30,267,450
$29,672,070
25.1%
24.6%
26.2%
Supply Expense % Net Patient Revenue
2.0%
0.5%
Supply Expense per EIPA
$2,418
$2,523
($25)
-1.0%
$2,393
1,626
1,625
11
1,636
0.7%
Total Admissions

Total Patient Days
8,032
8,243
8,564
6.6%
532

(32)
-1.0%
3,110
Total EIPAs
3,078
3,021

IP Surgeries
6.7%
284
313
334

OP Surgeries
574
Total Surgeries
549
603

-9.0%
140
3.6%

169
Outpatient Cath Lab Procedures 215 290 (75) (54) 21 6 -25.9% 290
175
Site Performance Summary
St. Elizabeth Youngstown's expense arrived at budget for the month at $418 under budget (0% variance). Net revenue fell short of
target by 595K (2%) despite admissions and surgeries that closely tracked with budgeted expectations. The primary driver of this
variance was Medical Surgical supplies, Blood and Other Non Medical expense. O/P registrations came in 7.9% under budget while
O/P revenue fell short by 3.9%. Supply expense per EIPA arrived right at budget, indicating overall approriate use of supplies during
the period. Drug expense exceeded budget by $124K driven by increased antineoplastic and thrombolytic purchases. Despite the
O/P shortfall Cath Lab remained strong with volumes exceeding budget by 3% and prior-year by 28%. Stent expense and CRM
compared favorably with PY on similar product utilization. Surgical volume exceeded budget on strong outpatient volume with I/P
falling just short of plan. Implants were over budget $24K (1.3%) on the increased volume, while the facility was able to hold the line
on MedSurg spend, with this expense expense coming in $82K (3.4%) under budget. TAVR volume (7 procedures, $228K) was in-line
St. Elizabeth Youngstown Hospital Leader's Summary
with recent volume trends and exceeded PY by two ($65K). Implant Other exceeded budget by $53K, mainly driven by CardioMEMS
($39K) and Occluder PFO expense ($20K) as well as three EVAR/AAA procedures totaling $62K.
Key Challenges
Significant increase in Intuitive Surgical expense compared to PY ($69K vs. $36K).
Corresponding decrease in expense expected over next 2-3 months as instrument have 10-20
uses before requiring replacement.
Special Procedures up $87K on several high-dollar treatments/devices including $48K Sirtex SIR-
Med/Surg
sphere radiation therapy (consider coding elsewhere) as well as 11 ea. ($31K) in EKOS catheters
Drugs experiencing an increase in utilization include the folloing: Herceptin (antineoplastic, up
$206K, $0 PY), Activase (thrombolytic, up $99K, 642%), and Neulasta (hematopoetic, up $11K,
12%)
Rx
TAVR volume in-line with budgeted expectations, no Intuity valves installed vs. 3 ea. PY ($36K
impact). ICD/pacers exceeded budget by 18K on similar volume to PY. Two SICDs were
implanted at a total cost of $52K
Implants Average stent cost decreased $144 ea. vs. PY on improved compliance with the Ministry's
contract strategy. Abbott vs. Boston Sci market share is 82%/17%
A $31,500 AAA case was performed - case included a rare hypogastric component.
Reimbursement for this procedure is under review.
Laboratoy supplies exceeded budget by $75K on flu-related volume increase, Austintown ED
came in $24K oover budget, Microbiology $28K over, Chemistry $18K over).
Other Expenses
Out of period expense of $25K for Linde bulk O2 invoices. SEYH Respiratory Director retired in
late 2017, some invoices in the transition not processed.
Actions Taken/Planned:
Medtronic DES evaluation is planned for 2/1 - 2/14. Physicians are engaged and actively
participating.
Working with Strategic Sourcing team on impacting price of the approved clinical trial of the
Vigilant X4 device. Cases held pending Ministry-approve pricing.
Reviewing utilization/inventory levels for daVinci disposables as well as account coding: 2018:
$29K Endomechanical, $28K Instruments, $12. K Med Surg 2017:
$36K, all to Med Surg
Reviewed Red Cross blood handling process after extreme spikes/credits in expense were
encoutered throughout MHY in Q4, 2017.